Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

High-Content Screening for Cryptosporidium Drug Discovery.

Love MS, McNamara CW.

Methods Mol Biol. 2020;2052:303-317. doi: 10.1007/978-1-4939-9748-0_17.

PMID:
31452169
2.

Advances in Antiwolbachial Drug Discovery for Treatment of Parasitic Filarial Worm Infections.

Bakowski MA, McNamara CW.

Trop Med Infect Dis. 2019 Jul 18;4(3). pii: E108. doi: 10.3390/tropicalmed4030108. Review.

3.

Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis.

Lunde CS, Stebbins EE, Jumani RS, Hasan MM, Miller P, Barlow J, Freund YR, Berry P, Stefanakis R, Gut J, Rosenthal PJ, Love MS, McNamara CW, Easom E, Plattner JJ, Jacobs RT, Huston CD.

Nat Commun. 2019 Jun 27;10(1):2816. doi: 10.1038/s41467-019-10687-y.

4.

Peyssonnosides A-B, Unusual Diterpene Glycosides with a Sterically Encumbered Cyclopropane Motif: Structure Elucidation Using an Integrated Spectroscopic and Computational Workflow.

Khatri Chhetri B, Lavoie S, Sweeney-Jones AM, Mojib N, Raghavan V, Gagaring K, Dale B, McNamara CW, Soapi K, Quave CL, Polavarapu PL, Kubanek J.

J Org Chem. 2019 Jul 5;84(13):8531-8541. doi: 10.1021/acs.joc.9b00884. Epub 2019 Jun 18.

5.

Novel chemical starting points for drug discovery in leishmaniasis and Chagas disease.

Roquero I, Cantizani J, Cotillo I, Manzano MP, Kessler A, Martín JJ, McNamara CW.

Int J Parasitol Drugs Drug Resist. 2019 Aug;10:58-68. doi: 10.1016/j.ijpddr.2019.05.002. Epub 2019 May 22.

6.

Discovery of Kirromycins with Anti- Wolbachia Activity from Streptomyces sp. CB00686.

Xu Z, Fang SM, Bakowski MA, Rateb ME, Yang D, Zhu X, Huang Y, Zhao LX, Jiang Y, Duan Y, Hull MV, McNamara CW, Shen B.

ACS Chem Biol. 2019 Jun 21;14(6):1174-1182. doi: 10.1021/acschembio.9b00086. Epub 2019 May 10.

PMID:
31074963
7.

Discovery of short-course antiwolbachial quinazolines for elimination of filarial worm infections.

Bakowski MA, Shiroodi RK, Liu R, Olejniczak J, Yang B, Gagaring K, Guo H, White PM, Chappell L, Debec A, Landmann F, Dubben B, Lenz F, Struever D, Ehrens A, Frohberger SJ, Sjoberg H, Pionnier N, Murphy E, Archer J, Steven A, Chunda VC, Fombad FF, Chounna PW, Njouendou AJ, Metuge HM, Ndzeshang BL, Gandjui NV, Akumtoh DN, Kwenti TDB, Woods AK, Joseph SB, Hull MV, Xiong W, Kuhen KL, Taylor MJ, Wanji S, Turner JD, Hübner MP, Hoerauf A, Chatterjee AK, Roland J, Tremblay MS, Schultz PG, Sullivan W, Chu XJ, Petrassi HM, McNamara CW.

Sci Transl Med. 2019 May 8;11(491). pii: eaav3523. doi: 10.1126/scitranslmed.aav3523.

PMID:
31068442
8.

A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors.

Jumani RS, Hasan MM, Stebbins EE, Donnelly L, Miller P, Klopfer C, Bessoff K, Teixeira JE, Love MS, McNamara CW, Huston CD.

Nat Commun. 2019 Apr 23;10(1):1862. doi: 10.1038/s41467-019-09880-w.

9.

Modular, stereocontrolled Cβ-H/Cα-C activation of alkyl carboxylic acids.

Shang M, Feu KS, Vantourout JC, Barton LM, Osswald HL, Kato N, Gagaring K, McNamara CW, Chen G, Hu L, Ni S, Fernández-Canelas P, Chen M, Merchant RR, Qin T, Schreiber SL, Melillo B, Yu JQ, Baran PS.

Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8721-8727. doi: 10.1073/pnas.1903048116. Epub 2019 Apr 17.

10.

Antibacterial Oligomeric Polyphenols from the Green Alga Cladophora socialis.

Lavoie S, Sweeney-Jones AM, Mojib N, Dale B, Gagaring K, McNamara CW, Quave CL, Soapi K, Kubanek J.

J Org Chem. 2019 May 3;84(9):5035-5045. doi: 10.1021/acs.joc.8b03218. Epub 2019 Apr 3.

11.

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis.

Baragaña B, Forte B, Choi R, Nakazawa Hewitt S, Bueren-Calabuig JA, Pisco JP, Peet C, Dranow DM, Robinson DA, Jansen C, Norcross NR, Vinayak S, Anderson M, Brooks CF, Cooper CA, Damerow S, Delves M, Dowers K, Duffy J, Edwards TE, Hallyburton I, Horst BG, Hulverson MA, Ferguson L, Jiménez-Díaz MB, Jumani RS, Lorimer DD, Love MS, Maher S, Matthews H, McNamara CW, Miller P, O'Neill S, Ojo KK, Osuna-Cabello M, Pinto E, Post J, Riley J, Rottmann M, Sanz LM, Scullion P, Sharma A, Shepherd SM, Shishikura Y, Simeons FRC, Stebbins EE, Stojanovski L, Straschil U, Tamaki FK, Tamjar J, Torrie LS, Vantaux A, Witkowski B, Wittlin S, Yogavel M, Zuccotto F, Angulo-Barturen I, Sinden R, Baum J, Gamo FJ, Mäser P, Kyle DE, Winzeler EA, Myler PJ, Wyatt PG, Floyd D, Matthews D, Sharma A, Striepen B, Huston CD, Gray DW, Fairlamb AH, Pisliakov AV, Walpole C, Read KD, Van Voorhis WC, Gilbert IH.

Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7015-7020. doi: 10.1073/pnas.1814685116. Epub 2019 Mar 20.

12.

Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.

Jacobs RT, Lunde CS, Freund YR, Hernandez V, Li X, Xia Y, Carter DS, Berry PW, Halladay J, Rock F, Stefanakis R, Easom E, Plattner JJ, Ford L, Johnston KL, Cook DAN, Clare R, Cassidy A, Myhill L, Tyrer H, Gamble J, Guimaraes AF, Steven A, Lenz F, Ehrens A, Frohberger SJ, Koschel M, Hoerauf A, Hübner MP, McNamara CW, Bakowski MA, Turner JD, Taylor MJ, Ward SA.

J Med Chem. 2019 Mar 14;62(5):2521-2540. doi: 10.1021/acs.jmedchem.8b01854. Epub 2019 Feb 26.

13.

Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.

Antonova-Koch Y, Meister S, Abraham M, Luth MR, Ottilie S, Lukens AK, Sakata-Kato T, Vanaerschot M, Owen E, Jado JC, Maher SP, Calla J, Plouffe D, Zhong Y, Chen K, Chaumeau V, Conway AJ, McNamara CW, Ibanez M, Gagaring K, Serrano FN, Eribez K, Taggard CM, Cheung AL, Lincoln C, Ambachew B, Rouillier M, Siegel D, Nosten F, Kyle DE, Gamo FJ, Zhou Y, Llinás M, Fidock DA, Wirth DF, Burrows J, Campo B, Winzeler EA.

Science. 2018 Dec 7;362(6419). pii: eaat9446. doi: 10.1126/science.aat9446.

14.

The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis.

Janes J, Young ME, Chen E, Rogers NH, Burgstaller-Muehlbacher S, Hughes LD, Love MS, Hull MV, Kuhen KL, Woods AK, Joseph SB, Petrassi HM, McNamara CW, Tremblay MS, Su AI, Schultz PG, Chatterjee AK.

Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10750-10755. doi: 10.1073/pnas.1810137115. Epub 2018 Oct 3.

15.

The Deconstructed Granuloma: A Complex High-Throughput Drug Screening Platform for the Discovery of Host-Directed Therapeutics Against Tuberculosis.

Huang L, Kushner NL, Theriault ME, Pisu D, Tan S, McNamara CW, Petrassi HM, Russell DG, Brown AC.

Front Cell Infect Microbiol. 2018 Aug 14;8:275. doi: 10.3389/fcimb.2018.00275. eCollection 2018.

16.

Author Correction: A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.

Roth A, Maher SP, Conway AJ, Ubalee R, Chaumeau V, Andolina C, Kaba SA, Vantaux A, Bakowski MA, Thomson-Luque R, Adapa SR, Singh N, Barnes SJ, Cooper CA, Rouillier M, McNamara CW, Mikolajczak SA, Sather N, Witkowski B, Campo B, Kappe SHI, Lanar DE, Nosten F, Davidson S, Jiang RHY, Kyle DE, Adams JH.

Nat Commun. 2018 Jun 8;9(1):2317. doi: 10.1038/s41467-018-04817-1.

17.

A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.

Roth A, Maher SP, Conway AJ, Ubalee R, Chaumeau V, Andolina C, Kaba SA, Vantaux A, Bakowski MA, Thomson-Luque R, Adapa SR, Singh N, Barnes SJ, Cooper CA, Rouillier M, McNamara CW, Mikolajczak SA, Sather N, Witkowski B, Campo B, Kappe SHI, Lanar DE, Nosten F, Davidson S, Jiang RHY, Kyle DE, Adams JH.

Nat Commun. 2018 May 9;9(1):1837. doi: 10.1038/s41467-018-04221-9. Erratum in: Nat Commun. 2018 Jun 8;9(1):2317.

18.

Cell-based screen for discovering lipopolysaccharide biogenesis inhibitors.

Zhang G, Baidin V, Pahil KS, Moison E, Tomasek D, Ramadoss NS, Chatterjee AK, McNamara CW, Young TS, Schultz PG, Meredith TC, Kahne D.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):6834-6839. doi: 10.1073/pnas.1804670115. Epub 2018 May 7.

19.

Herbicidins from Streptomyces sp. CB01388 Showing Anti- Cryptosporidium Activity.

Chen JJ, Rateb ME, Love MS, Xu Z, Yang D, Zhu X, Huang Y, Zhao LX, Jiang Y, Duan Y, McNamara CW, Shen B.

J Nat Prod. 2018 Apr 27;81(4):791-797. doi: 10.1021/acs.jnatprod.7b00850. Epub 2018 Feb 22.

PMID:
29469575
20.

A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.

Jumani RS, Bessoff K, Love MS, Miller P, Stebbins EE, Teixeira JE, Campbell MA, Meyers MJ, Zambriski JA, Nunez V, Woods AK, McNamara CW, Huston CD.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01505-17. doi: 10.1128/AAC.01505-17. Print 2018 Apr.

21.

Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis.

Hulverson MA, Choi R, Arnold SLM, Schaefer DA, Hemphill A, McCloskey MC, Betzer DP, Müller J, Vidadala RSR, Whitman GR, Rivas KL, Barrett LK, Hackman RC, Love MS, McNamara CW, Shaughnessy TK, Kondratiuk A, Kurnick M, Banfor PN, Lynch JJ, Freiberg GM, Kempf DJ, Maly DJ, Riggs MW, Ojo KK, Van Voorhis WC.

Int J Parasitol. 2017 Oct;47(12):753-763. doi: 10.1016/j.ijpara.2017.08.006. Epub 2017 Sep 9.

22.

A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.

Love MS, Beasley FC, Jumani RS, Wright TM, Chatterjee AK, Huston CD, Schultz PG, McNamara CW.

PLoS Negl Trop Dis. 2017 Feb 3;11(2):e0005373. doi: 10.1371/journal.pntd.0005373. eCollection 2017 Feb.

23.

Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor.

Goldgof GM, Durrant JD, Ottilie S, Vigil E, Allen KE, Gunawan F, Kostylev M, Henderson KA, Yang J, Schenken J, LaMonte GM, Manary MJ, Murao A, Nachon M, Stanhope R, Prescott M, McNamara CW, Slayman CW, Amaro RE, Suzuki Y, Winzeler EA.

Sci Rep. 2016 Jun 13;6:27806. doi: 10.1038/srep27806.

24.

High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria.

Swann J, Corey V, Scherer CA, Kato N, Comer E, Maetani M, Antonova-Koch Y, Reimer C, Gagaring K, Ibanez M, Plouffe D, Zeeman AM, Kocken CH, McNamara CW, Schreiber SL, Campo B, Winzeler EA, Meister S.

ACS Infect Dis. 2016 Apr 8;2(4):281-293. Epub 2016 Feb 10.

25.

Establishing Equivalence of Electronic Clinician-Reported Outcome Measures.

Fuller RLM, McNamara CW, Lenderking WR, Edgar C, Rylands A, Feaster T, Sabatino D, Miller DS.

Ther Innov Regul Sci. 2016 Jan;50(1):30-36. doi: 10.1177/2168479015618693.

PMID:
30236021
26.

Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease.

Khare S, Roach SL, Barnes SW, Hoepfner D, Walker JR, Chatterjee AK, Neitz RJ, Arkin MR, McNamara CW, Ballard J, Lai Y, Fu Y, Molteni V, Yeh V, McKerrow JH, Glynne RJ, Supek F.

PLoS Pathog. 2015 Jul 17;11(7):e1005058. doi: 10.1371/journal.ppat.1005058. eCollection 2015 Jul.

27.

Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials.

Flannery EL, McNamara CW, Kim SW, Kato TS, Li F, Teng CH, Gagaring K, Manary MJ, Barboa R, Meister S, Kuhen K, Vinetz JM, Chatterjee AK, Winzeler EA.

ACS Chem Biol. 2015 Feb 20;10(2):413-20. doi: 10.1021/cb500616x. Epub 2014 Nov 5.

28.

Identification of pathogen genomic variants through an integrated pipeline.

Manary MJ, Singhakul SS, Flannery EL, Bopp SE, Corey VC, Bright AT, McNamara CW, Walker JR, Winzeler EA.

BMC Bioinformatics. 2014 Mar 3;15:63. doi: 10.1186/1471-2105-15-63.

29.

KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro.

Zeeman AM, van Amsterdam SM, McNamara CW, Voorberg-van der Wel A, Klooster EJ, van den Berg A, Remarque EJ, Plouffe DM, van Gemert GJ, Luty A, Sauerwein R, Gagaring K, Borboa R, Chen Z, Kuhen K, Glynne RJ, Chatterjee AK, Nagle A, Roland J, Winzeler EA, Leroy D, Campo B, Diagana TT, Yeung BK, Thomas AW, Kocken CH.

Antimicrob Agents Chemother. 2014;58(3):1586-95. doi: 10.1128/AAC.01927-13. Epub 2013 Dec 23.

30.

Targeting Plasmodium PI(4)K to eliminate malaria.

McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Simon O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman AM, Dechering KJ, Kumar TS, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Nagle A, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken CH, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT, Winzeler EA.

Nature. 2013 Dec 12;504(7479):248-253. doi: 10.1038/nature12782. Epub 2013 Nov 27.

31.

Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials.

Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, Kirk K.

Cell Host Microbe. 2013 Feb 13;13(2):227-37. doi: 10.1016/j.chom.2012.12.006.

32.

Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families.

Bopp SE, Manary MJ, Bright AT, Johnston GL, Dharia NV, Luna FL, McCormack S, Plouffe D, McNamara CW, Walker JR, Fidock DA, Denchi EL, Winzeler EA.

PLoS Genet. 2013;9(2):e1003293. doi: 10.1371/journal.pgen.1003293. Epub 2013 Feb 7.

33.

Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design.

Harbut MB, Patel BA, Yeung BK, McNamara CW, Bright AT, Ballard J, Supek F, Golde TE, Winzeler EA, Diagana TT, Greenbaum DC.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21486-91. doi: 10.1073/pnas.1216016110. Epub 2012 Dec 11.

34.

Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin.

Hoepfner D, McNamara CW, Lim CS, Studer C, Riedl R, Aust T, McCormack SL, Plouffe DM, Meister S, Schuierer S, Plikat U, Hartmann N, Staedtler F, Cotesta S, Schmitt EK, Petersen F, Supek F, Glynne RJ, Tallarico JA, Porter JA, Fishman MC, Bodenreider C, Diagana TT, Movva NR, Winzeler EA.

Cell Host Microbe. 2012 Jun 14;11(6):654-63. doi: 10.1016/j.chom.2012.04.015.

35.

Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.

Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA.

Science. 2011 Dec 9;334(6061):1372-7. doi: 10.1126/science.1211936. Epub 2011 Nov 17.

36.

A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor.

Nam TG, McNamara CW, Bopp S, Dharia NV, Meister S, Bonamy GM, Plouffe DM, Kato N, McCormack S, Bursulaya B, Ke H, Vaidya AB, Schultz PG, Winzeler EA.

ACS Chem Biol. 2011 Nov 18;6(11):1214-22. doi: 10.1021/cb200105d. Epub 2011 Sep 8.

37.

M1 protein allows Group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition.

Lauth X, von Köckritz-Blickwede M, McNamara CW, Myskowski S, Zinkernagel AS, Beall B, Ghosh P, Gallo RL, Nizet V.

J Innate Immun. 2009;1(3):202-14. doi: 10.1159/000203645. Epub 2009 Feb 20.

38.

Individual differences in reactivity to daily events: examining the roles of stability and level of self-esteem.

Greenier KD, Kernis MH, McNamara CW, Waschull SB, Berry AJ, Herlocker CE, Abend TA.

J Pers. 1999 Feb;67(1):185-208.

PMID:
10030023

Supplemental Content

Loading ...
Support Center